Results 81 to 90 of about 19,704 (200)
Peroxisome Proliferator Activator Receptor (PPAR) Γ Agonis Menurunkan Kadar Sitokin Anti Inflamasi TGF-β dan IL-10 pada Tikus Putih Wistar Model Inflamasi Vaskular [PDF]
, 2015 Inflamasi vaskular merupakan kondisi patologis yang mendasari terjadinya gangguan pada pembuluh darah. NADPH oksidase merupakan enzim sentral yang mengaktivasi kaskade inflamasi sehingga dihasilkan superoxide (Reactive Oxygen Species), aktivasi sel ...
Hidayat, R. (Rachmat)
core
Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.This review explores how surface‐coated inorganic nanomaterials are chemically engineered for advanced drug delivery. It highlights design principles, coating strategies, and biomedical applications, emphasizing how surface chemistry governs biocompatibility, targeting, and controlled release.
Hossein Daneshgar +4 more
wiley +1 more source
Drug-mediated shortening of action potentials in LQTS2 hiPSC-cardiomyocytes [PDF]
, 2017 Cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hiPSCs) are now a well-established modality for modeling genetic disorders of the heart.
Denning, Chris +6 more
core +3 more sources
Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing
ELECTROPHORESIS, Volume 47, Issue 2, Page 175-184, February 2026.ABSTRACT Following the valsartan scandal in 2018, the testing of drug substances and drug products for N‐nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC–MS/MS, GC–MS, and GC–MS/MS.
Felix Bredendiek +2 more
wiley +1 more source
The Iraqi Journal of Medical Sciences, 2018 Background: Osteoarthritis (OA) is a degenerative joint disease caused by gradual loss of cartilage. Telmisartan is an angiotensin II receptor antagonist, and act as a partial agonist on the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-?
Sarah A. Hmood +3 more
doaj +6 more sources
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008 [PDF]
, 2008 This article summarizes the results of a number of clinical trials in the field of cardiovascular medicine which were presented during the Hotline and Clinical Trial Update Sessions at the annual meeting of the European Society of Cardiology, held in ...
Adam, Oliver +4 more
core +2 more sources
Telmisartan and cardioprotection
Vascular Health and Risk Management, 2011 Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions,
Akhrass, Philippe R, McFarlane, Samy I
openaire +4 more sources
The Iraqi Journal of Medical Sciences, 2018 Background: Osteoarthritis (OA) is a degenerative joint disease caused by gradual loss of cartilage. Telmisartan is an angiotensin II receptor antagonist, and act as a partial agonist on the nuclear peroxisome proliferator-activated receptor-gamma (PPAR ...
Sarah Hmood +3 more
doaj +1 more source